2284P Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
A. Ackermann(Boehringer Ingelheim (Germany)), Jörg F. Rippmann(Boehringer Ingelheim (Germany)), Patrik Erlmann(Boehringer Ingelheim (Austria)), Sven Mostböck(Boehringer Ingelheim (Austria)), Birgit Stierstorfer(Ludwig-Maximilians-Universität München), Jutta Petschenka(Boehringer Ingelheim (Germany)), Valerie L. Herrmann(Boehringer Ingelheim (Germany)), Dominik Hotter(Boehringer Ingelheim (Germany)), Knut Elbers, J-G. Wojtyniak(Boehringer Ingelheim (Germany)), Tanja Schönberger(University of Tübingen), Philipp Mueller, Tobias Nolden(Tyrolit (Austria))
Cited by 0
Related Papers
IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP
|Nature Communications|2017|290
Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity
|Cell Host & Microbe|2016|272
Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins
|Cell Reports|2019|195
IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation
|Cell Host & Microbe|2019|138